Cancer rates returned to near prepandemic levels in 2021, however, distant-stage breast cancer incidence surpassed expectations, signaling potential COVID-19 screening disruption effects.
By:
Kerri Miller
Conexiant September 25, 2024
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
Bio:Kerri Miller is Editor at Conexiant, a medical content platform producing clinically-oriented articles, commentaries, and perspectives for healthcare professionals. In her role, she oversees editorial content across specialties including internal medicine, endocrinology, dermatology, family medicine, neurology, pediatrics, and more, ensuring evidence-based reporting and editing. ([conexiant.com](https://conexiant.com/author/kerri-miller/?utm_source=openai))
She contributes to Conexiant by writing or editing pieces on regulatory issues, clinical developments, and emerging healthcare trends. Recent examples include menopauses hormone therapy and FDA regulation of medical devices. ([conexiant.com](https://conexiant.com/obgyn/articles/rethinking-menopause-hormone-therapy/?utm_source=openai))
